Medifast (MED) Equity Average (2011 - 2026)

Medifast has reported Equity Average for 16 years, with the latest figure at $198.3 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 5.81% year-over-year to $198.3 million; the trailing twelve-month figure through Mar 2026 stood at $198.3 million (down 5.81% YoY), and the FY2025 full-year result was $204.5 million, down 0.62% from the prior year.
• Equity Average for Q1 2026 stood at $198.3 million, down from $206.8 million in the prior quarter.
• The five-year high for Equity Average was $215.4 million in Q3 2025, with the low at $140.0 million in Q3 2022.
• Historically, Equity Average has averaged $192.7 million across 5 years, with a median of $206.2 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average declined 28.38% — and 2023, when it surged 35.21%.
• Medifast's Equity Average stood at $152.8 million in 2022, then grew by 29.11% to $197.3 million in 2023, then advanced by 5.81% to $208.7 million in 2024, then fell by 0.92% to $206.8 million in 2025, then declined by 4.12% to $198.3 million in 2026.
• The last three Equity Average figures came in at $198.3 million (Q1 2026), $206.8 million (Q4 2025), and $215.4 million (Q3 2025), per Business Quant data.